Floatz logo

Dc-Cik

Postoperative Complications

China Meitan General HospitalCell therapyPhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Postoperative Complications cohort.

Asset / SponsorPhaseRating
Calcium folinate pentahydrate
China Meitan General Hospital
Phase 4BB
FLUOROURACILUM
China Meitan General Hospital
Phase 4BB
Eloxatin
China Meitan General Hospital
Phase 4BB
DEXAMETHASONE
Rigshospitalet, Denmark
Phase 4BB
Precedex Inj★
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB

View all 18 →

Same molecule, other indications

Dc-Cik is also rated in:

Cytokine-induced Killer CellsDormant
BB
Indicative ·
67 / 100
View asset →
Multiple Drug UseDormant
BB
Indicative ·
65 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →